Hemlibra (emicizumab) is a brand-name drug that’s prescribed to prevent bleeding episodes due to hemophilia A in adults and children. Hemlibra comes as a subcutaneous injection that’s given once per ...

“Current treatment regimens for hemophilia A can require frequent intravenous infusions. We are encouraged that HEMLIBRA prophylaxis administered by injection under the skin once every four weeks ...

HEMLIBRA has strong market potential due to its unique, subcutaneous prophylactic treatment for Hemophilia A, including patients with and without factor VIII inhibitors. With increasing global ...

– There is limited information and treatment guidance on moderate and mild hemophilia A, which can lead to delayed or missed diagnoses of bleeding episodes – – Hemlibra is approved to treat people of ...

– Second interim analysis of the STASEY study, including data from 193 patients, consistent with results from Phase III HAVEN studies, with no new safety signals identified – – STASEY is the largest ...

Genentech announced that the Food and Drug Administration (FDA) has approved Hemlibra (emicizumab-kxwh) injection for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in ...

U.S. regulators have approved the first new treatment in nearly two decades to prevent internal bleeding in certain patients with hemophilia. This photo provided by Genentech, Inc. shows a package of ...

Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that the U.S. Food and Drug Administration (FDA) has approved HEMLIBRA ® (US generic name: emicizumab-kxwh), a treatment for hemophilia A ...

Non-inhibitor hemophilia A patients are now eligible for health insurance coverage for the subcutaneous hemophilia treatment 'Hemlibra'. JW Pharmaceutical announced on the 2nd that the health ...

Hemlibra (emicizumab-kxwh) is a prescription drug that helps prevent or reduce the frequency of bleeding episodes from hemophilia A. The drug comes as a solution for injecting under the skin every 1, ...